Karyopharm Therapeutics (NASDAQ:KPTI) Stock Rating Upgraded by BidaskClub

Share on StockTwits

BidaskClub upgraded shares of Karyopharm Therapeutics (NASDAQ:KPTI) from a sell rating to a hold rating in a research note issued to investors on Saturday morning, BidAskClub reports.

KPTI has been the topic of several other research reports. Zacks Investment Research downgraded Karyopharm Therapeutics from a hold rating to a sell rating in a research report on Saturday, March 2nd. HC Wainwright reiterated a buy rating on shares of Karyopharm Therapeutics in a research report on Wednesday, February 27th. JPMorgan Chase & Co. downgraded Karyopharm Therapeutics from an overweight rating to a neutral rating and reduced their price objective for the stock from $21.00 to $7.00 in a research report on Friday, March 1st. Wedbush reduced their price objective on Karyopharm Therapeutics from $19.00 to $14.00 and set an outperform rating on the stock in a research report on Monday, February 25th. Finally, ValuEngine downgraded Karyopharm Therapeutics from a hold rating to a sell rating in a research report on Tuesday, March 19th. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and five have issued a buy rating to the company’s stock. Karyopharm Therapeutics has an average rating of Hold and an average price target of $17.75.

NASDAQ KPTI opened at $5.89 on Friday. The stock has a market capitalization of $385.85 million, a P/E ratio of -1.88 and a beta of 2.62. The firm has a 50 day moving average price of $5.48. Karyopharm Therapeutics has a 1-year low of $3.92 and a 1-year high of $21.71. The company has a debt-to-equity ratio of 0.98, a quick ratio of 6.19 and a current ratio of 6.19.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its earnings results on Thursday, May 9th. The company reported ($1.09) earnings per share for the quarter, missing the consensus estimate of ($0.84) by ($0.25). The firm had revenue of $0.16 million during the quarter, compared to analysts’ expectations of $0.75 million. Karyopharm Therapeutics had a negative net margin of 1,005.85% and a negative return on equity of 119.66%. Research analysts forecast that Karyopharm Therapeutics will post -3.81 EPS for the current fiscal year.

Large investors have recently bought and sold shares of the business. PNC Financial Services Group Inc. raised its position in Karyopharm Therapeutics by 660.0% in the fourth quarter. PNC Financial Services Group Inc. now owns 3,800 shares of the company’s stock valued at $36,000 after purchasing an additional 3,300 shares during the period. BNP Paribas Arbitrage SA grew its stake in shares of Karyopharm Therapeutics by 169,300.0% in the first quarter. BNP Paribas Arbitrage SA now owns 10,164 shares of the company’s stock valued at $59,000 after buying an additional 10,158 shares in the last quarter. Legal & General Group Plc grew its stake in shares of Karyopharm Therapeutics by 31.3% in the fourth quarter. Legal & General Group Plc now owns 10,116 shares of the company’s stock valued at $95,000 after buying an additional 2,411 shares in the last quarter. Metropolitan Life Insurance Co. NY grew its stake in shares of Karyopharm Therapeutics by 356.6% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 16,275 shares of the company’s stock valued at $152,000 after buying an additional 12,711 shares in the last quarter. Finally, Weiss Multi Strategy Advisers LLC grew its stake in shares of Karyopharm Therapeutics by 24.4% in the fourth quarter. Weiss Multi Strategy Advisers LLC now owns 25,000 shares of the company’s stock valued at $234,000 after buying an additional 4,905 shares in the last quarter. Institutional investors own 84.20% of the company’s stock.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor(KPT-330), which is in Phase IIb clinical study in treatments of refractory multiple myeloma; Phase Ib/II clinical study in combination with backbone treatments for multiple myeloma patients; Phase III clinical trial in combination with Velcade (bortezomib) and dexamethasone for multiple myeloma patients; Phase IIb clinical study in diffuse large B-cell lymphoma; Phase II/III clinical study in liposarcoma; Phase III clinical trial in endometrial cancer; and Phase II clinical trial in glioblastoma multiforme.

Featured Story: What is the downside to momentum investing?

Analyst Recommendations for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.